Evidence map›Paper›PMID 32525984›Full record

ArticleNucleic acids research2020

Tissue- and development-stage-specific mRNA and heterogeneous CNV signatures of human ribosomal proteins in normal and cancer samples.

Anshuman Panda, Anupama Yadav, Huwate Yeerna, Amartya Singh, Michael Biehl, Markus Lux, Alexander Schulz, Tyler Klecha, Sebastian Doniach, Hossein Khiabanian and 3 more

Open access · goldAbstract read
In one paragraph

Article in Nucleic acids research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. The ribosomal landscape in influenza A virus infection: from molecular mechanisms to clinical relevance.European respiratory review : an official journal of the European Respiratory Society · 2026
    Review
  4. Article
  5. Article
  6. Mechanisms of ribosomopathy and phase separation-related ribosomopathy.Journal of Zhejiang University. Science. B · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Specialized Ribosomes in Health and Disease.International journal of molecular sciences · 2023
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

Anshuman PandaRutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA.
Anupama YadavCenter for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Huwate YeernaMoores Cancer Center, University of California San Diego, La Jolla, CA 92103, USA.
Amartya SinghRutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA.
Michael BiehlBernoulli Institute for Mathematics, Computer Science and Artificial Intelligence, University of Groningen, Nijenborgh 9, NL-9747 AG Groningen, The Netherlands.
Markus LuxCognitive Interaction Technology (CITEC), Bielefeld University, Inspiration 1, D-33619 Bielefeld, Germany.
Alexander SchulzCognitive Interaction Technology (CITEC), Bielefeld University, Inspiration 1, D-33619 Bielefeld, Germany.
Tyler KlechaDepartment of Molecular Biology and Biochemistry, Rutgers University, Piscataway, NJ,08854, USA.
Sebastian DoniachDepartment of Applied Physics, Stanford University, Palo Alto, CA 94305, USA.
Hossein KhiabanianRutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA.
Shridar GanesanRutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA.
Pablo TamayoMoores Cancer Center, University of California San Diego, La Jolla, CA 92103, USA.
Gyan BhanotRutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA.
Rutgers, The State University of New Jersey · USBielefeld University · DEUniversity of California San Diego · USHarvard University · USPalo Alto University · USUniversity of Groningen · NL

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jesse Nodora · 1985 to 2026
$124.9M
TRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Tracie Saunders · 1997 to 2026
$94.5M
Genomic Analysis of Network Perturbations in Human DiseaseP50HG004233 · NHGRI · DANA-FARBER CANCER INST · PI VIDAL, MARC · 2007 to 2017
$31.6M
Using Networks to Seed Hierarchical Whole-cell Models of CancerU54CA209891 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI IDEKER, TREY, KROGAN, NEVAN J · 2017 to 2021
$10.9M
Supporting Integrative Genomic Analysis Users with GenePatternR01GM074024 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MESIROV, JILL P. · 2005 to 2019
$6.6M
A Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic StatesU01CA217885 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI COHEN, EZRA, KAUFMAN, DAN S. · 2017 to 2021
$5.1M
Resource ProjectU41HG001715 · NHGRI · DANA-FARBER CANCER INST · PI CALDERWOOD, MICHAEL A, HILL, DAVID E. · 2015 to 2017
$4.7M
Stimulating Neo-Antigen Specific T Cell Responses in Head and Neck CancersU01DE028227 · NIDCR · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI GUTKIND, JORGE SILVIO, RAO, ANJANA · 2018 to 2022
$4.6M
GenePattern and GenePattern Notebook: Integrative 'Omic Analysis for Cancer ResearchU24CA248457 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MESIROV, JILL P., TAMAYO, PABLO · 2020 to 2024
$4.6M
Next-generation Functional Genetic Screening of Un-screenable TraitsR01HG009285 · NHGRI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MALI, PRASHANT, TAMAYO, PABLO · 2017 to 2020
$4.2M
Rewiring of regulatory networks in breast cancer by transcription factor isoformsU01CA232161 · NCI · DANA-FARBER CANCER INST · PI BULYK, MARTHA L, FUXMAN BASS, JUAN IGNACIO · 2018 to 2022
$4.1M
Supporting and evolving Gene Set Enrichment Analysis and the Molecular Signatures Database for cancer researchU24CA220341 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MESIROV, JILL P., TAMAYO, PABLO · 2018 to 2022
$3.4M
NCI NIH HHS P30 CA023100NCI NIH HHS P30 CA072720NCI NIH HHS R01 CA172513NCI NIH HHS R01 CA202752NCI NIH HHS R01 CA226803NCI NIH HHS R01 CA233662NCI NIH HHS R01 CA243547NCI NIH HHS U01 CA217885NCI NIH HHS U01 CA232161NCI NIH HHS U24 CA194107NCI NIH HHS U24 CA220341NCI NIH HHS U24 CA248457NCI NIH HHS U54 CA209891NHGRI NIH HHS P50 HG004233NHGRI NIH HHS R01 HG009285NHGRI NIH HHS U41 HG001715NIDCR NIH HHS R01 DE026870NIDCR NIH HHS U01 DE028227NIGMS NIH HHS R01 GM074024
6 · The paper itself

Abstract

We give results from a detailed analysis of human Ribosomal Protein (RP) levels in normal and cancer samples and cell lines from large mRNA, copy number variation and ribosome profiling datasets. After normalizing total RP mRNA levels per sample, we find highly consistent tissue specific RP mRNA signatures in normal and tumor samples. Multiple RP mRNA-subtypes exist in several cancers, with significant survival and genomic differences. Some RP mRNA variations among subtypes correlate with copy number loss of RP genes. In kidney cancer, RP subtypes map to molecular subtypes related to cell-of-origin. Pan-cancer analysis of TCGA data showed widespread single/double copy loss of RP genes, without significantly affecting survival. In several cancer cell lines, CRISPR-Cas9 knockout of RP genes did not affect cell viability. Matched RP ribosome profiling and mRNA data in humans and rodents stratified by tissue and development stage and were strongly correlated, showing that RP translation rates were proportional to mRNA levels. In a small dataset of human adult and fetal tissues, RP protein levels showed development stage and tissue specific heterogeneity of RP levels. Our results suggest that heterogeneous RP levels play a significant functional role in cellular physiology, in both normal and disease states.

Indexed as

DNA Copy Number VariationsRNA, MessengerAnimalsCell LineDatabases, GeneticFetusGene Expression Regulation, DevelopmentalGene Expression Regulation, NeoplasticHumansMiceNeoplasmsProtein BiosynthesisRibosomal ProteinsRibosomesRibosomal ProteinsRNA, Messenger

Identifiers

PMID32525984
PMCPMC7367157
OpenAlexW3035245624

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.